Applied Genomic Technology Capital Fund LP

CIK 1399779 · last filed 2015-07-16

Applied Genomic Technology Capital Fund LP is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2009. The most recent filing, for BGMD, was dated Jul 16, 2015. Across all open-market trades the lifetime net is +$6.0M, making them a net buyer over the disclosed history. The firm reports its address in Cambridge, MA. 10 SEC filings were submitted jointly with Flagship Pioneering Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

2

Total Filings

3

Lifetime Open-Market Net

$6.00M

Filer Profile

Reported Address

C/O FLAGSHIP VENTURES
ONE MEMORIAL DRIVE, 7TH FLOOR
CAMBRIDGE, MA 02142

Phone

(617) 868-1888

Related Filers

Flagship Pioneering Inc. — 10 joint filings, latest 2015-07-29

AGTC ADVISORS FUND LP — 8 joint filings, latest 2015-07-16

NewcoGen Group, Inc. — 7 joint filings, latest 2015-07-29

Flagship Ventures Fund 2004 L P — 6 joint filings, latest 2009-08-10

Edwin Kania — 6 joint filings, latest 2015-07-16

NOUBAR AFEYAN — 4 joint filings, latest 2015-07-29

Flagship Ventures General Partner LLC — 4 joint filings, latest 2009-08-10

Flagship Ventures 2007 General Partner LLC — 1 joint filings, latest 2015-07-16

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
BG Medicine, Inc. (BGMD) Delisted	10%+ Owner	31,431	—	—	$6.00M	2	2015-07-16
HELICOS BIOSCIENCES CORP (HLCS) Delisted	10%+ Owner	—	—	—	$0	1	2009-08-10

Recent Filings

3 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2015-07-16	BG Medicine, Inc. (BGMD) Delisted	Mixed	—	$0	EDGAR
2011-02-11	BG Medicine, Inc. (BGMD) Delisted	Mixed	+7,474,380	$6.00M	EDGAR
2009-08-10	HELICOS BIOSCIENCES CORP (HLCS) Delisted	Grant (A)	—	$0	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.